Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Generating revenue from ideas involves innovation and market understanding. Learn how to monetize your concepts effectively.
17,831 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
When a CEO unloads a big chunk of stock, investors take note. This article digs into sentinelone's sold over 39,000 s...
Brace yourself for a clear, investor-friendly read on chord energy (chrd) 2025 Q4 results. This deep dive breaks down...
Credo Technology signals a 50% growth pace for the year as AI data-center demand drives its connectivity chips. Q3 re...
As 2026 unfolds, AT&T and Verizon compete for income and growth. This analysis weighs dividend safety, leverage, and ...
Oracle confronts a heavy debt burden and sweeping layoffs as it presses ahead with a three-step transformation, raisi...
Insider stock moves can be alarming, but they aren’t always a red flag. This guide explains how to read a fastly stoc...
Energy Transfer sits at the heart of U.S. energy infrastructure. This guide explains when energy transfer stock right...
Benchmark lowered its Bakkt price target by about 47%, arguing that near-term monetization remains elusive as the com...
Step into the world of a self-made millionaire through an in-depth millionaire interview. Learn concrete habits, habi...
When a founder-led brand hits a leadership cliff, markets react fast. This article explains why holding's stock crash...
Hut 8's stock surged on news of a landmark AI data center deal valued at $9.8 billion, positioning the crypto miner t...